Forum for Science, Industry and Business
Sponsored by:     Siemens  n-tv 
Search our Site:

Topic (optional):

 

Home Reports Health and Medicine Content

Early predictor of breast cancer aggressiveness

next article
28.06.2004

 


Physicians may be able to make early decisions on the best treatment for breast cancer, thanks to research published in Breast Cancer Research today. A gene involved in the adhesion of cells is less active in breast tumors with a poor prognosis than those that are less aggressive, researchers found.Measuring the activity of the ALCAM gene in primary breast tumors could give physicians advanced warning about the likely clinical outcome of the disease. This should help them decide whether to prescribe a more aggressive treatment regimen, such as chemotherapy, much earlier in the diagnostic process.


Dr Judy King and colleagues, from University of South Alabama and University of Wales College of Medicine, compared the expression of the gene for the Activated Leukocyte Cell Adhesion Molecule (ALCAM) in normal breast tissue and tissue samples from primary breast tumors. To do this they counted the number of mRNA transcripts of the ALCAM gene in the different samples.

The researchers found that the ALCAM gene was significantly less active in higher-grade tumors compared to lower-grade tumors, and in tumors with a worse prognosis compared to those with a better prognosis.“Tumors from patients who died of breast cancer had significantly lower levels of ALCAM transcripts than those with primary tumors but no metastatic disease or local recurrence,” write the researchers.

They continue: “The data clearly suggest that decreased ALCAM expression in the primary tumor is of clinical significance in breast cancer, and that reduced expression indicates a more aggressive phenotype and poor prognosis.” They suggest that quantitative PCR, to measure the number of ALCAM transcripts in a tissue sample from a primary breast tumor, could be used to identify these more aggressive tumors at an early stage.

As ALCAM is involved in keeping cells together in a clump, the researchers hypothesize that reduced expression of the gene might allow the tumor cells to separate from one another. This would allow cells to enter the circulation and promote the formation of secondary tumors, which makes the cancer harder to treat.

Gemma Bradley | Source: alphagalileo
Further information: www.biomedcentral.com

next article

More articles from Health and Medicine:

nachricht Interferon alpha can delay full onset of type I diabetes
03.07.2009 | University of Texas Health Science Center at Houston

nachricht Infants should be screened for hip trouble
03.07.2009 | American Academy of Orthopaedic Surgeons

All articles from Health and Medicine >>>

B2B Search

Product / Service
Company / Organisation

Latest News

The least sea ice in 800 years

03.07.2009 | Earth Sciences

Astronomer's new guide to the galaxy: largest map of cold dust revealed

03.07.2009 | Physics and Astronomy

Interferon alpha can delay full onset of type I diabetes

03.07.2009 | Health and Medicine

VideoLinks

Event News

New Worlds - New Solutions - Research and Innovation as a Basis for Developing Europe in a Global Context

29.06.2009 | Event News

6th BMBF Forum for Sustainability "Research for Sustainability - One Step Further"

19.06.2009 | Event News

2nd ISPIM Innovation Symposium - Stimulating Recovery The Role of Innovation Management

02.06.2009 | Event News